Growth Hormone Deficiency – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of growth hormone deficiency comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report diagnosed incidence and diagnosed lifetime prevalence of growth hormone deficiency for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.
Clarivate Epidemiology’s growth hormone deficiency forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of growth hormone deficiency over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts two growth hormone deficiency patient populations:
- Diagnosed lifetime prevalent cases.
- Diagnosed incident cases.
Note: Coverage may vary by country.
Table of contents
- Growth Hormone Deficiency - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Diagnosed Incidence of Growth Hormone Deficiency per Year per 100,000 People of All Ages in 2021 and 2041
- Diagnosed Incidence of Growth Hormone Deficiency per Year per 100,000 People of All Ages in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Incident Cases of Growth Hormone Deficiency Over the Next 20 Years
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Incident Cases of Growth Hormone Deficiency Over the Next 20 Years
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Dr. Harpreet Kaur, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she was awarded a National Clinical Research Fellowship by the Indian Council of Medical Research (ICMR) and worked as a clinical scientist in the broader area of adolescent reproductive health. She obtained her master’s degree in social epidemiology from the Tata Institute of Social Sciences in Mumbai and graduated with a degree in dentistry from Punjab University in Chandigarh.
Stephanie Niquita Phankon, M.B.B.S., M.P.H., Manager, Epidemiology. Ms. Phankon’s expertise is in autoimmune and inflammatory diseases and hematological malignancies. She holds a master’s in public health specializing in epidemiology from TISS in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China. She has been trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects.